Need help?  
[email protected]
Pinson and Tang CDI Pocket Guide
Pinson & Tang

Deep Vein Thrombosis and Pulmonary Embolism

March 11, 2022

Most pulmonary emboli (PE) arise from deep venous thrombosis (DVT) of the proximal veins of the lower extremities (iliac, femoral, and popliteal). The clinical presentation of pulmonary embolism is variable and often nonspecific, making the diagnosis challenging. DVTs are dangerous since they can result in PE which can be deadly.

The underlying causes of DVT and PE may be hereditary (genetic mutations) or acquired. Hereditary causes are rare and include Factor V Leiden, elevated Factor VIII, and deficiencies in protein S, protein C, and antithrombin.

Acquired causes are more common. Precipitating factors for DVT and subsequent PE, include:

  • Immobilization due to hospitalization, travel, obesity, or stroke;
  • Adverse effects of drugs, such as steroids, oral contraceptives, anticoagulants, and heparin;
  • Clinical conditions including major trauma, pregnancy, malignancy, diabetes, and myeloproliferative disorders; and
  • Autoimmune diseases such as lupus anticoagulant and antiphospholipid syndrome.

Immobilization leads to venous stasis with accumulation of clotting factors and fibrin, resulting in blood clot formation. 

Healthcare-associated venous thromboembolism (VTE) is a result of hospitalization, surgery, or other healthcare treatment or procedure. According to the CDC, although anyone can develop a DVT, over half are related to a recent hospitalization or surgery and most occur after discharge; approximately 70% of these could be prevented.   

Acute, Chronic, or "History of" DVT and PE

The acuity of DVT and PE should be identified for clinical and coding purposes:

  • Acute,
  • Chronic, or
  • “History of”

Acute DVT or PE is usually treated with heparin-type medications for immediate anticoagulation to prevent further clot growth. None of these medications actually “treat” the acute DVT. The acute blood clots are usually dissolved spontaneously by endogenous processes in the veins within a few days, not by heparin, Coumadin, or Xarelto. A transition is then made to intermediate term (3-12 months) Coumadin, or more recently Xarelto, to prevent recurrent DVT/PE.

The first episode of PE or DVT is acute until the clot(s) have resolved – approximately 10-14 days. After that it should be considered resolved, i.e., “history of”, even though anticoagulation to prevent a recurrence is continued up to one year. One or more recurrences represents chronic PE or DVT for which life-long anticoagulation is necessary.

The acute episode of DVT and PE ends when the patient is stabilized, transitioned to Coumadin, Eliquis or Xarelto, and discharged. If such a patient is admitted with “history of DVT (or PE)” and without a recurrent episode, the correct status is “history of” DVT/PE, not acute or chronic DVT/PE. A subsequent episode of DVT or PE requiring admission would constitute a recurrent episode of acute DVT.

© 2022 Copyright Pinson & Tang LLC

Receive updates on new Resources, Products, and Events.

This topic is sourced directly from the original 
CDI Pocket Guide®. 

Click HERE to learn more about this essential resource.
At Pinson & Tang, we provide trusted, clear, and consistent teaching and resources for coding specialists, CDI specialists, and physicians.

Contact Info

Contact Us
Copyright ©2022 Pinson & Tang.
chevron-downellipsis-vlong-arrow-left linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram